ClinicalTrials.gg
CompletedNCT02917941Updated Jan 12, 2021Results posted

A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 2 interventional study of Ixazomib and Lenalidomide in Relapsed and/or Refractory Multiple Myeloma, sponsored by Takeda. Completed at 21 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-01-12.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies testing ixazomib in Multiple Myeloma — 1 open to participants now, 7 under way, none of them phase 3. ixazomib · Multiple Myeloma.

Enrollment
44th of 68
34 · median 48
Started
2016
with 4 others
Phase 2
38 of 68
none open now
Registered
36th of 68
by date
Lead sponsor
10 of 68
Takeda

Among the 68 studies testing ixazomib in Multiple Myeloma, this one is the 44th largest by enrollment, is one of 5 that started in 2016, is one of 38 in phase 2, and was the 36th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 68 studies testing ixazomib in Multiple Myeloma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ixazomib

ixazomib: first FDA approval 2015 (NINLARO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies testing ixazomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ixazomib plus lenalidomide and dexamethasone in Japanese participants with relapsed and/or refractory multiple myeloma (RRMM).

Read the detailed description

This is a phase 2, open label, single arm, multicenter study to evaluate the efficacy and safety of ixazomib plus lenalidomide and dexamethasone in Japanese participants with relapsed and/or refractory multiple myeloma (MM). The participants population will consist of adult men and women who have a confirmed diagnosis of MM, who have received 1 to 3 prior lines of therapy, and who meet other outlined eligibility criteria. Participants will receive study drug (ixazomib 4.mg) on Days 1, 8, and 15 plus lenalidomide (25 mg) on Days 1 through 21 and dexamethasone (40 mg) on Days 1, 8, 15, and 22 of a 28-day cycle. Participants may continue to receive treatment until progressive disease (PD) or unacceptable toxicity, whichever comes first. Dose modifications may be made based on toxicities. Participant with a low creatinine clearance \< 60 mL/min will receive a reduced lenalidomide dose of 10 mg once daily on Days 1 through 21 of a 28-day cycle. The lenalidomide dose may be escalated to 15 mg once daily after 2 cycles if the participant is not responding to treatment and is tolerating the treatment. If renal function normalizes (ie, creatinine clearance >= 60 mL/min) and the participant continues to tolerate this treatment, lenalidomide may then be escalated to 25 mg once daily.

Treatment periods will be defined as 28-day cycles. Participant will be seen at regular treatment cycle intervals while they are participating in the study: four times a treatment cycle for the first 2 cycles, twice a treatment cycle for the 3rd cycle, and then once a treatment cycle for the remainder of their participation in the active treatment and, if applicable, the progression free survival (PFS) and overall survival (OS) follow-up phases of the study.

Response will be assessed by investigator according to the International Myeloma Working Group criteria for all participants every 4 weeks until PD. Central laboratory data will be used for serum M-protein, urine M-protein and serum free light chain. All participants will be followed for survival after progression. Participants will be contacted every 12 weeks until death or termination of the study by the sponsor.

The study will be closed at 24 months from the enrollment of the last participant.

03

Conditions studied

  • Relapsed and/or Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female Japanese participants 20 years of age or older.
  2. Multiple myeloma (MM) diagnosed according to standard criteria either currently or at the time of initial diagnosis.

    The initial diagnosis must be symptomatic MM, although the disease does not need to be symptomatic.

  3. Participants must have defined by at least 1 of the following 3 measurements based on central laboratory data:

    • Serum M-protein: >=1 g/dL (>= 10 g/L).
    • Urine M-protein: >=200 mg/24 hours.
    • Serum free light chain assay: involved free light chain level >=10 mg/dL (>= 100 mg/L), provided that the serum free light chain ratio is abnormal.
  4. Participants with RRMM who have received 1 to 3 prior therapies.

    This participant population includes the following 3 categories of participants:

    • Participants who relapsed from their therapy(s) but were not refractory to any previous therapy.
    • Participants who were refractory to all lines of previous therapy(s) (ie, participants who have never responded to any therapies received).
    • Participants who were relapsed from at least 1 AND additionally were refractory to at least 1 line of therapy. For the purposes of this study, refractory MM is defined as PD on therapy or PD within 60 days after the last dose of a given therapy.

    A line of therapy is defined as 1 or more cycles of a planned treatment program. This may consist of 1 or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. For example, a planned treatment approach of induction therapy followed by stem cell transplantation, followed by maintenance is considered 1 line of therapy. Autologous and allogenic transplants are permitted.

  5. Participants must meet the following clinical laboratory criteria:

    • (ANC) >= 1,000/mm3, >= 8 g/dL and count >= 75,000/mm3. Platelet transfusions to help participants meet eligibility criteria are not allowed within 3 days prior to screening.
    • Total =\< 1.5 x the (ULN).
    • (ALT) and aspartate aminotransferase (AST) =\< 3 x ULN.
    • Calculated >= 30 mL/min.
  6. (ECOG) performance status of 0, 1, or 2.
  7. Participants who received prior allogenic transplant must have no active (GVHD).
  8. Participants who meet the following conditions:

    Female participants who:

    • Are for at least 24 months before the screening visit, OR
    • Are surgically sterile, OR
    • Females of must:

      1. Have a negative pregnancy test with a sensitivity of at least 25 mIU/mL within 10 to 14 days and again within 24 hours prior to starting Cycle 1 of lenalidomide
      2. Agree to practice true abstinence or to begin TWO reliable methods of (1 highly effective method and 1 additional effective method AT THE SAME TIME) for at least 28 days before starting the study treatment through 90 days after the last dose of the study treatment.
      3. Agree to ongoing pregnancy testing
      4. Adhere to the guidelines of the RevMate program

    Male participants, even if surgically sterilized (ie, status postvasectomy), must:

    • Agree to avoid sexual intercourse completely 90 days after the last dose of the study treatment.
    • Agree to practice true abstinence or to practice effective barrier contraception during the entire study treatment period and 90 days after the last dose of the study treatment if their partner is of childbearing potential, even if they have had a successful vasectomy, and
    • Adhere to the guidelines of the RevMate program
  9. Thromboembolism prophylaxis is required based on published standard or institutional standard of care.
  10. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.
  11. Participant is willing and able to adhere to the study visit schedule and other protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Participants who were to lenalidomide or proteasome inhibitor-based therapy at any line.

    Refractory disease is defined as PD on treatment or PD within 60 days after the last dose of a given therapy. Participants who progressed the disease after 60 days from the last dose of a given therapy will be considered relapsed and are eligible for inclusion in the study.

    Participants who were refractory to thalidomide-based therapy are eligible.

  2. Female participants who are breast feeding or pregnant.
  3. Failure to have fully recovered (ie, =\< Grade 1 toxicity) from the effects of prior chemotherapy (except for hair loss) regardless of the interval since the last treatment.
  4. Major surgery within 14 days before enrollment.
  5. Radiotherapy within 14 days before enrollment.
  6. Central nervous system involvement.
  7. Infection requiring systemic antibiotic therapy or other serious infection within 14 days before enrollment.
  8. Rash or pruritus requiring systemic medication within 14 days before enrollment.
  9. Diagnosis of Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome.
  10. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months before enrollment.
  11. Systemic treatment with strong cytochrome P450, family 3, subfamily A () inducers (rifampicin, carbamazepine, phenytoin), or St. John's wort within 14 days before enrollment.
  12. Ongoing or active systemic infection, known (HIV)- positive, known surface antigen seropositive or known virus (HCV)-RNA positive.

    Participants who have positive hepatitis B core antibody (HBcAb) can be enrolled but must have hepatitis B virus (HBV)-DNA negative. Participants who have positive hepatitis C antibody can be enrolled but must have HCV-RNA negative.

  13. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the participant inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens (eg, peripheral neuropathy that is Grade 1 with pain or Grade 2 or higher of any cause).
  14. Psychiatric illness/social situation that would limit compliance with study requirements.
  15. Known allergy to any of the study medications, their analogues, or in the various formulations of any agent.
  16. Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal condition that could interfere with the oral absorption or tolerance of treatment.
  17. Diagnosed or treated for another within 2 years before enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
  18. Participants who have participated in a clinical trial of ixazomib, or have been treated with ixazomib.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg

    Ixazomib 4 mg, capsules, orally on Days 1, 8, and 15 plus lenalidomide 25 mg, capsule, orally, once daily on Days 1 through 21 and dexamethasone 40 mg, tablet, orally on Days 1, 8, 15, and 22 of a 28-day cycle up to 32 cycles.

    Drug: Ixazomib · Drug: Lenalidomide · Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Very Good Partial Response (VGPR) or Better Response (Complete Response (CR) + VGPR)

    Response was assessed using International Myeloma Working Group (IMWG) Criteria. CR was defined as negative immunofixation in serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. VGPR was defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours.

    Time frame: Up to approximately 33 months

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the time in months from the date of first study drug administration to the date of first documentation of PD or death from any cause, whichever occurred first. PD required one of the following: increase of ≥ 25% from nadir in: serum M-component (absolute increase ≥ 0.5 g/dl); urine M-component (absolute increase ≥ 200 mg/24 hours); in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase \> 10 mg/dl); development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \> 11.5 mg/dl) attributed solely to plasma cell proliferative disease.

    Time frame: Up to approximately 33 months

  2. Overall Response Rate (ORR)

    ORR:percentage of participants with CR including stringent complete response(sCR),VGPR,partial response(PR) per independent review committee(IRC)by IMWG criteria.CR: serum,urine -ve immunofixation; disappearance of soft tissue plasmacytomas,\<5%plasma cells in bone marrow(CR in those with only measurable disease by serum FLC levels=normal FLC ratio 0.26 to 1.65+CR criteria).sCR:CR+normal FLC ratio,absence of clonal plasma cells(immunohistochemistry)or 2-to 4-color flow cytometry.VGPR:serum,urine M-protein detectable by immunofixation,not by electrophoresis or ≥90%reduction,\<100mg/24hrs(VGPR in those with only measurable disease by serum FLC levels,requires\>90%decrease in involved-uninvolved FLC level difference).PR: ≥50%reduction of serum M protein+reduction in 24-hr urinary M protein by≥90%/ to\<200mg/24-hr or ≥50%decrease in difference between involved-uninvolved FLC levels/≥50%reduction in bone marrow plasma cells,if≥30%at baseline/≥50%soft tissue plasmacytoma size reduction.

    Time frame: Up to approximately 33 months

  3. Duration of Response (DOR)

    DOR was measured as time in months from date of first documentation of response, VGPR or better, and ORR (CR+PR (including sCR and VGPR) or better, to date of first documented PD among participants who responded to treatment. Response was assessed by investigator using IMWG Criteria. CR:negative immunofixation in serum and urine and; disappearance of any soft tissue plasmacytomas and;\<5% plasma cells in bone marrow. sCR:CR plus normal FLC ratio, absence of clonal plasma cells by immunohistochemistry or 2- to 4-color flow cytometry. VGPR:serum and urine M-protein detectable by immunofixation but not on electrophoresis/≥90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 hours. PR:≥50% reduction of serum M protein+reduction in 24-hour urinary M protein by ≥90%/ to \<200 mg/24-hour or ≥50% decrease in difference between involved and uninvolved FLC levels/≥50% reduction in bone marrow plasma cells, if ≥30% at baseline/≥50% reduction in size of soft tissue plasmacytomas.

    Time frame: Up to approximately 33 months

  4. Time to Progression (TTP)

    TTP was measured as the time in months from the first dose of study treatment to the date of the first documented PD as assessed using IMWG criteria. PD required one of the following: increase of ≥ 25% from nadir in: serum M-component (absolute increase ≥ 0.5 g/dL); urine M-component (absolute increase ≥ 200 mg/24 hours); in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase \> 10 mg/dL); development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL) attributed solely to plasma cell proliferative disease.

    Time frame: Up to approximately 33 months

  5. Number of Participants With One or More Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it was related to the medicinal product. A TEAE is defined as any AE that occurred after administration of the first dose of any study drug through 30 days after the last dose of any study drug.

    Time frame: Up to approximately 33 months

  6. Number of Participants With NCI CTCAE Grade 3 or Higher TEAEs Related Laboratory Parameters

    Laboratory parameters included chemistry and hematology. An AE is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it was related to the medicinal product. A TEAE is defined as any AE that occurred after administration of the first dose of any study drug through 30 days after the last dose of any study drug. An AE was graded as per NCI CTCAE.

    Time frame: Up to approximately 33 months

  7. Number of Participants With NCI CTCAE Grade 3 or Higher TEAEs Related to Vital Signs

    Vital signs included temperature, blood pressure, heart rate, and respiratory rate. An AE is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it was related to the medicinal product. A TEAE is defined as any AE that occurred after administration of the first dose of any study drug through 30 days after the last dose of any study drug. An AE was graded as per NCI CTCAE.

    Time frame: Up to approximately 33 months

  8. Overall Survival (OS)

    OS was defined as the time from the date of first study drug administration to the date of death.

    Time frame: Up to approximately 33 months

07

Results

Posted Sep 18, 2020

Participant flow

Participants took part in the study at 16 investigative sites in Japan from 01 November 2016 to 31 August 2019.

Treatment Period
Participant flow — Treatment Period
MilestoneIxazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Started34
Completed10
Not completed24
Withdrew: Adverse event11
Withdrew: Progressive disease11
Withdrew: Reason not specified2
Survival Follow-up Period
Participant flow — Survival Follow-up Period
MilestoneIxazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Started31
Completed26
Not completed5
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject4

Outcome measures

PrimaryPercentage of Participants With Very Good Partial Response (VGPR) or Better Response (Complete Response (CR) + VGPR)

Response was assessed using International Myeloma Working Group (IMWG) Criteria. CR was defined as negative immunofixation in serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. VGPR was defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours.

Time frame:
Up to approximately 33 months
Reported as:
Number · percentage of participants
Percentage of Participants With Very Good Partial Response (VGPR) or Better Response (Complete Response (CR) + VGPR)
percentage of participantsIxazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Percentage of Participants With Very Good Partial Response (VGPR) or Better Response (Complete Response (CR) + VGPR)50.0 (31.9 to 68.1)
SecondaryProgression-free Survival (PFS)

PFS was defined as the time in months from the date of first study drug administration to the date of first documentation of PD or death from any cause, whichever occurred first. PD required one of the following: increase of ≥ 25% from nadir in: serum M-component (absolute increase ≥ 0.5 g/dl); urine M-component (absolute increase ≥ 200 mg/24 hours); in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase \> 10 mg/dl); development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \> 11.5 mg/dl) attributed solely to plasma cell proliferative disease.

Time frame:
Up to approximately 33 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsIxazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Progression-free Survival (PFS)22.05 (17.28 to NA)
SecondaryOverall Response Rate (ORR)

ORR:percentage of participants with CR including stringent complete response(sCR),VGPR,partial response(PR) per independent review committee(IRC)by IMWG criteria.CR: serum,urine -ve immunofixation; disappearance of soft tissue plasmacytomas,\<5%plasma cells in bone marrow(CR in those with only measurable disease by serum FLC levels=normal FLC ratio 0.26 to 1.65+CR criteria).sCR:CR+normal FLC ratio,absence of clonal plasma cells(immunohistochemistry)or 2-to 4-color flow cytometry.VGPR:serum,urine M-protein detectable by immunofixation,not by electrophoresis or ≥90%reduction,\<100mg/24hrs(VGPR in those with only measurable disease by serum FLC levels,requires\>90%decrease in involved-uninvolved FLC level difference).PR: ≥50%reduction of serum M protein+reduction in 24-hr urinary M protein by≥90%/ to\<200mg/24-hr or ≥50%decrease in difference between involved-uninvolved FLC levels/≥50%reduction in bone marrow plasma cells,if≥30%at baseline/≥50%soft tissue plasmacytoma size reduction.

Time frame:
Up to approximately 33 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsIxazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Overall Response Rate (ORR)84.4 (67.2 to 94.7)
SecondaryDuration of Response (DOR)

DOR was measured as time in months from date of first documentation of response, VGPR or better, and ORR (CR+PR (including sCR and VGPR) or better, to date of first documented PD among participants who responded to treatment. Response was assessed by investigator using IMWG Criteria. CR:negative immunofixation in serum and urine and; disappearance of any soft tissue plasmacytomas and;\<5% plasma cells in bone marrow. sCR:CR plus normal FLC ratio, absence of clonal plasma cells by immunohistochemistry or 2- to 4-color flow cytometry. VGPR:serum and urine M-protein detectable by immunofixation but not on electrophoresis/≥90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 hours. PR:≥50% reduction of serum M protein+reduction in 24-hour urinary M protein by ≥90%/ to \<200 mg/24-hour or ≥50% decrease in difference between involved and uninvolved FLC levels/≥50% reduction in bone marrow plasma cells, if ≥30% at baseline/≥50% reduction in size of soft tissue plasmacytomas.

Time frame:
Up to approximately 33 months
Reported as:
Median · months
Duration of Response (DOR)
monthsIxazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
VGPR or betterNA (16.03 to NA)
ORR21.65 (16.03 to NA)
SecondaryTime to Progression (TTP)

TTP was measured as the time in months from the first dose of study treatment to the date of the first documented PD as assessed using IMWG criteria. PD required one of the following: increase of ≥ 25% from nadir in: serum M-component (absolute increase ≥ 0.5 g/dL); urine M-component (absolute increase ≥ 200 mg/24 hours); in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase \> 10 mg/dL); development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL) attributed solely to plasma cell proliferative disease.

Time frame:
Up to approximately 33 months
Reported as:
Median · months
Time to Progression (TTP)
monthsIxazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Time to Progression (TTP)22.57 (17.51 to NA)
SecondaryNumber of Participants With One or More Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it was related to the medicinal product. A TEAE is defined as any AE that occurred after administration of the first dose of any study drug through 30 days after the last dose of any study drug.

Time frame:
Up to approximately 33 months
Reported as:
Count of participants · Participants
Number of Participants With One or More Treatment-emergent Adverse Events (TEAEs)
ParticipantsIxazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Number of Participants With One or More Treatment-emergent Adverse Events (TEAEs)34
SecondaryNumber of Participants With NCI CTCAE Grade 3 or Higher TEAEs Related Laboratory Parameters

Laboratory parameters included chemistry and hematology. An AE is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it was related to the medicinal product. A TEAE is defined as any AE that occurred after administration of the first dose of any study drug through 30 days after the last dose of any study drug. An AE was graded as per NCI CTCAE.

Time frame:
Up to approximately 33 months
Reported as:
Count of participants · Participants
Number of Participants With NCI CTCAE Grade 3 or Higher TEAEs Related Laboratory Parameters
ParticipantsIxazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Platelet count decreased7
Neutrophil count decreased6
White blood cell count decreased3
Lymphocyte count decreased1
Alanine aminotransferase increased1
Aspartate aminotransferase increased1
Lipase increased1
Blood creatine phosphokinase increased1
SecondaryNumber of Participants With NCI CTCAE Grade 3 or Higher TEAEs Related to Vital Signs

Vital signs included temperature, blood pressure, heart rate, and respiratory rate. An AE is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it was related to the medicinal product. A TEAE is defined as any AE that occurred after administration of the first dose of any study drug through 30 days after the last dose of any study drug. An AE was graded as per NCI CTCAE.

Time frame:
Up to approximately 33 months
Reported as:
Count of participants · Participants
Number of Participants With NCI CTCAE Grade 3 or Higher TEAEs Related to Vital Signs
ParticipantsIxazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Hypertension1
Hypotension1
SecondaryOverall Survival (OS)

OS was defined as the time from the date of first study drug administration to the date of death.

Time frame:
Up to approximately 33 months
Reported as:
Median · months
Overall Survival (OS)
monthsIxazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Overall Survival (OS)NA (30.85 to NA)

Adverse events

Collected over Up to approximately 33 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg3/34 (8.8%)12/34 (35.3%)34/34 (100%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventIxazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
PneumoniaInfections and infestations3/34
DiarrhoeaGastrointestinal disorders2/34
FallInjury, poisoning and procedural complications2/34
CellulitisInfections and infestations1/34
InfluenzaInfections and infestations1/34
Inguinal herniaGastrointestinal disorders1/34
VomitingGastrointestinal disorders1/34
Subdural haemorrhageInjury, poisoning and procedural complications1/34
Femoral neck fractureInjury, poisoning and procedural complications1/34
Platelet count decreasedInvestigations1/34
Most frequent other events
Showing 10 of 61
Most frequent other events
EventIxazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
ConstipationGastrointestinal disorders17/34
Upper respiratory tract infectionInfections and infestations16/34
DiarrhoeaGastrointestinal disorders14/34
RashSkin and subcutaneous tissue disorders12/34
NasopharyngitisInfections and infestations11/34
NauseaGastrointestinal disorders10/34
Platelet count decreasedInvestigations9/34
InfluenzaInfections and infestations7/34
DysgeusiaNervous system disorders7/34
Peripheral sensory neuropathyNervous system disorders7/34

Baseline characteristics

Full Analysis Set (FAS) is defined as all participants who received at least one dose of the study drug during the treatment period.

Age, Continuous
Age, Continuous(years)Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Mean65.2 ± 8.57
Sex: Female, Male
Sex: Female, Male(Participants)Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Female15
Male19
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Ethnicity — Not Hispanic or Latino34
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Race — Asian (Japanese)34
Region of Enrollment
Region of Enrollment(Participants)Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Japan34
Height
Height(centimeter (cm))Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Mean159.88 ± 9.738
Weight
Weight(kilogram (kg))Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Mean60.36 ± 12.444
Body Surface Area
Body Surface Area(square meter (m^2))Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
Mean1.632 ± 0.2076
08

Study locations

21 sites
  • Nagoya, Aichi, Japan
  • Narita, Chiba, Japan
  • Shibukawa, Gunma, Japan
  • Fukuyama, Hiroshima, Japan
  • Kobe, Hyogo, Japan
  • Sagamihara, Kanagawa, Japan
  • Sendai, Miyagi, Japan
  • Ikoma, Nara, Japan
  • Sunto-gun, Shizuoka, Japan
  • Utsunomiya, Tochigi, Japan
  • Bunkyo-ku, Tokyo, Japan
  • Koto-ku, Tokyo, Japan
  • Shibuya-ku, Tokyo, Japan
  • Shinjuku-ku, Tokyo, Japan
  • Tachikawa, Tokyo, Japan
  • Chiba, Japan
  • Fukuoka, Japan
  • Ibaragi, Japan
  • Niigata, Japan
  • Okayama, Japan
  • Osaka, Japan
09

References and documents

Publications

  • Iida S, Izumi T, Komeno T, Terui Y, Chou T, Ikeda T, Berg D, Fukunaga S, Sugiura K, Sasaki M. A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma. Int J Clin Oncol. 2022 Jan;27(1):224-233. doi: 10.1007/s10147-021-02030-7. Epub 2021 Oct 2. PubMed 34599726 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Aug 2019, 33 months.

Results were first posted in Sep 2020, 1 year after primary completion.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 33 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2016
First posted
Sep 28, 2016
StartActual
Nov 1, 2016
Primary completionActual
Aug 31, 2019
CompletionActual
Aug 31, 2019
Results first posted
Sep 18, 2020
Last update
Jan 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02917941
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 28, 2016
Start date
Nov 1, 2016
Primary completion
Aug 31, 2019
Completion
Aug 31, 2019
Results posted
Sep 18, 2020
Last update
Jan 12, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ixazomib · Lenalidomide · Dexamethasone

Start the discussion